Last year marked the first time that erythropoietins were not the top-selling biotech drugs. Stacy Lawrence looks at the biopharmaceuticals that have usurped them.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Supplementary information
Supplementary Table 1 (download DOC )
Major biologics. (DOC 34 kb)
Related links
Related links
Related links in Nature Research
2004 approvals: the demise of the blockbuster?
Amgen's TPO mimic faces stiff competition
Biotech drug market steadily expands
Web links
Rights and permissions
About this article
Cite this article
Lawrence, S. Billion dollar babies—biotech drugs as blockbusters. Nat Biotechnol 25, 380–382 (2007). https://doi.org/10.1038/nbt0407-380
Published:
Issue date:
DOI: https://doi.org/10.1038/nbt0407-380
